Parkinson’s disease polygenic risk score is not associated with impulse control disorders: a longitudinal study
Objective: To examine the relationship between a polygenic risk score (GRS) associated with Parkinson’s disease (PD) and impulse control disorders (ICDs) in PD. Background: Genome…Impulse control disorders and (romantic) jealousy in Parkinson’s disease: a patients’ vs. partners’ perspective
Objective: To compare self-reported symptoms of (romantic) jealousy and impulse control disorders (ICD) in Parkinson’s disease (PD) patients to those reported by their partners. Background:…Longitudinal analysis of the relation between trajectories of dopaminergic agonists use and BMI in Parkinson’s disease
Objective: To describe the longitudinal relation between dopaminergic agonists (DA) use and change of BMI in a longitudinal cohort of PD patients followed annually up…Long-term apomorphine infusion (APO) users versus short-term APO users: What is the reason to discontinue therapy? A multi-centre study
Objective: To evaluate the long-term efficacy of APO in PD patients treated at two specialist centres in Spain and Thailand, and to determine the reasons…Predictors of refractory impulse control disorder to dopamine agonists substitution therapy in Parkinson’s disease patients
Objective: This study was aimed to investigate a predictive factor of refractory impulse control disorder (ICD) in patients with Parkinson’s disease (PD) who participated in…Olfactory Hallucinations Induced by Pramipexole Treatment in Parkinson’s Disease
Objective: In the treatment of Parkinson’s disease, dopamine agonists are among the preferred treatment options, particularly in the treatment of young Parkinson’s patients. The known…A study for expanding application sites of rotigotine transdermal patch
Objective: We examined to see whether to expand application sites of RTP other than the approved application sites. Background: Rotigotine transdermal patch (RTP) is a dopamine…The Frequency, Causes and Risk Factors of Discontinuation of Dopamine Agonists in Parkinson’s Disease Patients
Objective: To determine the incidence, causes and risk factors of dopamine agonists (pramipexole and ropinirole) discontinuation in Parkinson’s disease patients. Background: Ropinirole and pramipexole are…Effect of dopamine agonists versus levodopa as initial treatment in Parkinson’s Disease
Objective: We evaluated the efficacy of different starting drugs in the treatment of Parkinson's disease (PD), in order to further explore the initial therapy of…Characteristics of dopaminergic treatments in advanced Parkinson’s before levodopa-carbidopa intestinal gel infusion: Data from 107 tested patients
Objective: To describe the characteristics of dopaminergic treatments in a large group of patients with advanced Parkinson’s Disease (APD) in which current non-invasive therapy (oral,…
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- …
- 13
- Next Page »